Liposomal doxorubicin coated with polyethylene glycol data

SEQU (formerly Liposome Technology Inc., Menlo Park, Calif.) said that two dose-ranging, Phase I trials of the agent in a total of 56 patients showed a better safety profile than that of the free chemotherapeutic, with no cardiotoxicity.

As published in the Journal of Clinical Oncology, skin and mucosal toxicities were the dose-limiting events, associated with higher doses and faster rates of infusion. ...